Sarepta Faces Investor Suit Over Gene Therapy-Linked Deaths
By Emilie Ruscoe · June 27, 2025, 10:09 PM EDT
Biopharmaceutical company Sarepta Therapeutics Inc. is facing a proposed investor class action after the deaths of two patients being treated with one of its therapies prompted regulatory scrutiny, with investors claiming...
To view the full article, register now.